{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:50:06Z","timestamp":1769017806628,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40265-020-01326-8","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T15:29:09Z","timestamp":1591198149000},"page":"915-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Cabotegravir Plus Rilpivirine: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"A.","family":"Markham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"12","key":"1326_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124\u201335.","journal-title":"N Engl J Med"},{"key":"1326_CR2","unstructured":"Janssen Pharmaceuticals. Janssen announces Health Canada approval of CABENUVA\u2122, the first long-acting regimen for the treatment of HIV [media release]. 20 Mar 2020. https:\/\/www.janssen.com."},{"key":"1326_CR3","unstructured":"ViiV Healthcare. ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy [media release]. 3 Nov 2015. https:\/\/www.viivhealthcare.com."},{"key":"1326_CR4","unstructured":"Tibotec Pharmaceuticals. EDURANT\u00ae (Rilpivirine) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in treatment-na\u00efve adults with HIV-1 [media release]. 23 Sep 2011. https:\/\/www.jnj.com\/."},{"key":"1326_CR5","unstructured":"Janssen Pharmaceuticals. Complete response letter issued from U.S. FDA for investigational long-Acting HIV regimen [media release]. 21 Dec 2019. https:\/\/www.janssen.com."},{"key":"1326_CR6","unstructured":"ViiV Healthcare ULC. VOCABRIATM (cabotegravir tablets), CABENUVA\u2122 (cabotegravir extended release injectable suspension and rilpivirine extended release injectable suspension): Canadian product monograph. 2020. https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viiv-healthcare\/en_GB\/medicines\/CABENUVA-VOCABRIA_PM_18-Mar-2020.pdf. Accessed 3 Apr 2020."},{"key":"1326_CR7","unstructured":"Janssen Pharmaceuticals. Janssen to progress collaboration with ViiV Healthcare to develop the first long acting two drug injectable regimen for treatment of HIV infection [media release]. 7 Jan 2016. https:\/\/www.jnj.com."},{"issue":"10","key":"1326_CR8","doi-asserted-by":"publisher","first-page":"e01299-18","DOI":"10.1128\/AAC.01299-18","volume":"62","author":"RA Smith","year":"2018","unstructured":"Smith RA, Wu VH, Zavala CG, et al. In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother. 2018;62(10):e01299-18.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"1326_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","volume":"15","author":"SJ Smith","year":"2018","unstructured":"Smith SJ, Zhao XZ, Burke TR Jr, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):37.","journal-title":"Retrovirology"},{"key":"1326_CR10","unstructured":"Janssen Pharmaceuticals. EDURANT\u00ae (rilpivirine): US prescribing Information. 2019. https:\/\/www.edurant.com\/hcp\/prescribing-information.html. Accessed 2 Apr 2020."},{"issue":"6","key":"1326_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cpdd.272","volume":"5","author":"Y Lou","year":"2016","unstructured":"Lou Y, Buchanan AM, Chen S, et al. Effect of cabotegravir on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(6):509\u201316.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1326_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1310\/hct1405-192","volume":"14","author":"W Spreen","year":"2013","unstructured":"Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192\u2013203.","journal-title":"HIV Clin Trials"},{"issue":"5","key":"1326_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67(5):481\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1326_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67(5):487\u201392.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"1326_CR15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"1326_CR16","doi-asserted-by":"publisher","first-page":"e00487-17","DOI":"10.1128\/AAC.00487-17","volume":"61","author":"SL Ford","year":"2017","unstructured":"Ford SL, Sutton K, Lou Y, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017;61(10):e00487-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"1326_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/bcp.13236","volume":"83","author":"C Trezza","year":"2017","unstructured":"Trezza C, Ford SL, Gould E, et al. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel\/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017;83(7):1499\u2013505.","journal-title":"Br J Clin Pharmacol"},{"key":"1326_CR18","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study [abstract no.34]. In: Conference on Retroviruses and Opportunistic Infections. 2020."},{"key":"1326_CR19","unstructured":"Orkin C. Long-acting cabotegravir\u00a0+\u00a0rilpivirine for HIV treatment: FLAIR week 96 results [abstract no. 482-PS]. In: Conference on Retroviruses and Opportunistic Infections. 2020."},{"issue":"10101","key":"1326_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499\u2013510.","journal-title":"Lancet"},{"key":"1326_CR21","doi-asserted-by":"crossref","unstructured":"Margolis D, Sutton K, De Vente J, et al. Long term efficacy, safety and durability of CAB and RPV as two drug oral maintenance therapy: LATTE week 312 results [abstract 2840]. In: IDWeek 2019. 2019.","DOI":"10.1093\/ofid\/ofz359.145"},{"issue":"10","key":"1326_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","volume":"15","author":"DA Margolis","year":"2015","unstructured":"Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145\u201355.","journal-title":"Lancet Infect Dis"},{"key":"1326_CR23","unstructured":"ViiV Healthcare. Global HIV prevention study to stop early after ViiV Healthcare\u2019s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP [media release]. 2020. https:\/\/viivhealthcare.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01326-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T23:45:20Z","timestamp":1622677520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01326-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01326-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"3 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}